PT-141

PT-141 is a compound with an unusual scientific origin. In the late 1990s researchers at the University of Arizona were studying a synthetic α-MSH analogue — Melanotan II — as a research tool for skin pigmentation. During those studies the investigators noticed something that had nothing to do with tanning: unmistakable effects on sexual function in the participants. That accidental observation reframed the entire programme. Palatin Technologies picked up the molecule, and a subsequent structural refinement produced a cyclic heptapeptide labelled PT-141 (later given the international non-proprietary name 'bremelanotide') that carried the sexual-response activity without the pigmentation side of the parent compound's profile. That single observation is the reason this molecule ever became a drug.

PT-141's chemistry is best understood as a truncated, cyclised, and stabilised derivative of α-MSH. The final molecule is a seven-amino-acid cyclic peptide with acetylated N-terminus and specific D-amino-acid substitutions. Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH is the amino-acid sequence that appears on the drug label. The design goal was potent, receptor-selective activity at MC4R (the central melanocortin subtype that engages the appetitive sexual-desire circuitry) with reduced activity at MC1R (which drives melanocyte activation and pigmentation).

Palatin first developed the compound as an intranasal formulation for male erectile dysfunction. That programme reached phase 3 but was discontinued in the mid-2000s after transient dose-related increases in blood pressure — a class effect of central melanocortin activation. The team reformulated the compound as a subcutaneous single-dose auto-injector and directed the next programme at hypoactive sexual desire disorder (HSDD) in premenopausal women. Two placebo-controlled phase-3 trials — RECONNECT-1 and RECONNECT-2 — met their primary endpoints on the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale, and on 2019-06-21 the FDA approved bremelanotide as Vyleesi for that indication. AMAG Pharmaceuticals marketed the product before returning US commercial rights to Palatin.

The regulatory identity of Vyleesi and the compound-name identity of PT-141 are not interchangeable in practice. Vyleesi is a specific single-dose 1.75 mg subcutaneous auto-injector with a defined indication, a contraindications list (uncontrolled hypertension, known cardiovascular disease), maximum-use guidance (1 dose per 24 h, 8 doses per month), and a label monitoring framework. Vials of compounded or research-supply bremelanotide sold under 'PT-141' are the same molecule but do not automatically inherit the approved-label safety and monitoring context. Consumers who assume the two are equivalent are importing the appeal of an FDA-approved drug into a supply chain that operates outside of it.

PT-141 is a compound with an unusual scientific origin. In the late 1990s researchers at the University of Arizona were studying a synthetic α-MSH analogue — Melanotan II — as a research tool for skin pigmentation. During those studies the investigators noticed something that had nothing to do with tanning: unmistakable effects on sexual function in the participants. That accidental observation reframed the entire programme. Palatin Technologies picked up the molecule, and a subsequent structural refinement produced a cyclic heptapeptide labelled PT-141 (later given the international non-proprietary name 'bremelanotide') that carried the sexual-response activity without the pigmentation side of the parent compound's profile. That single observation is the reason this molecule ever became a drug.

PT-141's chemistry is best understood as a truncated, cyclised, and stabilised derivative of α-MSH. The final molecule is a seven-amino-acid cyclic peptide with acetylated N-terminus and specific D-amino-acid substitutions. Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH is the amino-acid sequence that appears on the drug label. The design goal was potent, receptor-selective activity at MC4R (the central melanocortin subtype that engages the appetitive sexual-desire circuitry) with reduced activity at MC1R (which drives melanocyte activation and pigmentation).

Palatin first developed the compound as an intranasal formulation for male erectile dysfunction. That programme reached phase 3 but was discontinued in the mid-2000s after transient dose-related increases in blood pressure — a class effect of central melanocortin activation. The team reformulated the compound as a subcutaneous single-dose auto-injector and directed the next programme at hypoactive sexual desire disorder (HSDD) in premenopausal women. Two placebo-controlled phase-3 trials — RECONNECT-1 and RECONNECT-2 — met their primary endpoints on the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale, and on 2019-06-21 the FDA approved bremelanotide as Vyleesi for that indication. AMAG Pharmaceuticals marketed the product before returning US commercial rights to Palatin.

The regulatory identity of Vyleesi and the compound-name identity of PT-141 are not interchangeable in practice. Vyleesi is a specific single-dose 1.75 mg subcutaneous auto-injector with a defined indication, a contraindications list (uncontrolled hypertension, known cardiovascular disease), maximum-use guidance (1 dose per 24 h, 8 doses per month), and a label monitoring framework. Vials of compounded or research-supply bremelanotide sold under 'PT-141' are the same molecule but do not automatically inherit the approved-label safety and monitoring context. Consumers who assume the two are equivalent are importing the appeal of an FDA-approved drug into a supply chain that operates outside of it.

The pivotal clinical evidence supporting Vyleesi comes from RECONNECT-1 and RECONNECT-2 — two identically-designed 24-week randomised placebo-controlled phase-3 trials in premenopausal women with HSDD. Both trials met the co-primary endpoints on the FSFI desire domain and the Female Sexual Distress Scale — DAO Item 13. Effect sizes were statistically significant but numerically modest; on the FSFI desire domain, both trials showed placebo-adjusted improvements of ~0.35 units — meaningful in the context of the endpoint but not dramatic. The prescribing information reports response-rate analyses that put the treatment/placebo difference in the low double digits.

Mechanistic characterisation of bremelanotide's melanocortin receptor selectivity was published by the Molinoff/Diamond group at Palatin. The compound is potent at MC4R (which drives the sexual-response signal) with weaker but non-negligible activity at MC1R (pigmentation), MC3R and MC5R. The polypharmacology across the melanocortin family explains the compound's characteristic combination of desired CNS effects and off-target pigmentation with frequent dosing.

The earlier intranasal male-ED phase-3 program's blood-pressure safety signal has been the subject of significant post-hoc analysis. Central melanocortin activation is known to increase sympathetic outflow; the intranasal formulation produced peak plasma exposures that appeared to correlate with the observed BP effect. The subcutaneous 1.75 mg formulation was selected in part because its pharmacokinetics reduced the peak-to-trough excursion.

Vyleesi (bremelanotide) is an FDA-approved drug for HSDD in premenopausal women, approved on 2019-06-21. It is one of only two FDA-approved medications with a specific HSDD indication — the other being flibanserin (Addyi), an oral 5-HT1A agonist / 5-HT2A antagonist that predates it. The two are mechanistically unrelated and have very different administration paradigms (Vyleesi on-demand subcutaneous vs Addyi daily oral).

The earlier intranasal PT-141 programme for male erectile dysfunction reached phase 3 before being discontinued in the mid-2000s for transient dose-related blood-pressure elevations. That programme is a genuine part of the compound's development history but is not a supported indication today.

Vyleesi has not been submitted for centralised EMA approval, so it is not available in the EU as an authorised medicinal product.